Radius Health Inc (NASDAQ:RDUS) reported Q3 financial results Tuesday, with a net loss of $17.4 million, or $0.59 per share, narrowing from a net loss of $20.3 million, or $65.05 per share in the year-ago period. Analysts polled by Capital IQ were expecting a loss of $0.53 per share. The biopharmaceutical firm said its net loss decreased in Q3 relative to last year due to a decrease in research and development expenses, which was partially offset by an increase in general and administrative expenses. Radius Health Inc (NASDAQ:RDUS) did not report any revenues for the quarter. RDUS are trading in a 52-week range of $7.46 - $24.93.Click here for a free comprehensive Trend Analysis ReportThompson Creek Metals Company Inc (USA) (NYSE:TC) late Monday reported a non-GAAP net income of US$38.3 million, or US$0.17 per diluted share, for Q3 ended September 30 on revenues of US$229.3 million. The average estimate by analysts surveyed by Capital IQ was for diluted EPS of US$0.08 and revenues of US$212.05 million. In the same period last year, the mining company had a non-GAAP net loss of US$7.6 million, or US$0.04 per diluted share, on revenues of US$90.8 million.Thompson Creek Metals Company Inc (USA) (NYSE:TC) attributes the increase in revenues to stronger copper and gold revenues generated from the Mt. Milligan Mine. During the quarter, the firm produced 6.6 million pounds of molybdenum, 16.3 million pounds of copper, and 60,366 ounces of gold. For the year ended December 31, it expects production of 185,000 - 195,000 lbs of gold (from 165,000 - 175,000 lbs), 24 million - 27 million lbs of molybdenum (from 24 million - 28 million lbs), and 65 million - 75 million lbs of copper.Click here for a free comprehensive Trend Analysis ReportGenVec Inc (NASDAQ:GNVC) said it presented data showing the immune responses generated by its vaccine candidate, GV2311 that showed success in protecting against Respiratory Syncytial Virus. The data were presented at the 9th International Respiratory Syncytial Virus (RSV) Symposium being held in South Africa. RSV immunized mice had no detectable virus following low dose challenge, while breakthrough RSV replication in both lungs and noses was rapidly controlled upon high dose challenge. GV2311 immunization fully protected the lungs at both challenge doses with partial protection in noses, GenVec Inc (NASDAQ:GNVC) said.The studies also confirm that the major protective mechanism is through induction of antibodies against RSV, although antigen specific T cells contribute to viral clearance in the absence of antibody. The shares are trading with a 52-week range of $1.19 - $4.25.Click here for a free comprehensive Trend Analysis Report
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
